Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
May 2022
Historique:
received: 26 12 2021
accepted: 17 03 2022
pubmed: 30 4 2022
medline: 24 5 2022
entrez: 29 4 2022
Statut: ppublish

Résumé

The purpose of this study was to review the frequency and clinical presentation of the rarest clinical manifestations of systemic lupus erythematosus (SLE). A list of 6 rare SLE manifestations were defined: gastrointestinal, liver, pulmonary, cardiac, ocular and neurological manifestations. Each topic was assigned to a pair of authors to perform a literature search and article review. In total, 149 articles were included in the literature review: 37 for gastrointestinal manifestations, 6 for liver manifestations, 27 for pulmonary manifestations, 50 for cardiac manifestations, 16 for ocular manifestations, 13 for neurological manifestations. Gastrointestinal disorders included several clinical presentations with variable frequency (from 0.5% to 10.7% of the cases); liver involvement included lupus-related hepatitis (9.3%) and autoimmune hepatitis (2.3%). The rarest pulmonary manifestations identified were shrinking lung syndrome, described in 1.5% of patients, while interstitial lung disease and lupus pneumonia were reported in 4% and 3% of patients respectively. Myocarditis and pulmonary hypertension were also rarely described in SLE patients although ranging from 0.4-16% and 1-14% respectively, depending on the methodology used for its identification. Ocular manifestations in SLE included some rare manifestations (reported in less than 5% of patients) and lupus retinopathy that is described in 1.2-28.8% of patients depending on methods of ascertainment. Aseptic meningitis and chorea were also confirmed as very rare manifestations being reported in less than 1% and in 0.3-2.4% of cases respectively. The results of this literature review provide the basis for a better understanding of some less-known manifestations of SLE and for stressing the need for a higher awareness in diagnostic and therapeutic protocols regarding these rare disease aspects.

Identifiants

pubmed: 35485422
pii: 18242
doi: 10.55563/clinexprheumatol/jrz47c
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-102

Auteurs

Chiara Tani (C)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. chiaratani78@gmail.com.

Elena Elefante (E)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Laurent Arnaud (L)

Department of Rheumatology, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S 1109, Centre National de Référence des Maladies Auto-immunes Systémiques Rares (RESO), Strasbourg, France.

Sofia C Barreira (SC)

Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, and Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal.

Inita Bulina (I)

Reimatoloģijas centra vadītāja VSIA P. Stradiņa KUS IMK Reimatoloģijas centrs, LPRB (Latvijas pieaugušo Reimatoloģijas biedrība) valdes locekle, ERN ReCONNET Affiliated Partner representative of Latvia adults rheumatologists, Pauls Stradins Clinical University hospital, Internal Medicine Clinic, Centre of Rheumatology, Riga, Latvia.

Lorenzo Cavagna (L)

Rheumatology Division, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

Nathalie Costedoat-Chalumeau (N)

Service de Médecine Interne, Centre de Référence Maladies Autoimmunes et Systémiques Rares Île de France, APHP, Hôpital Cochin, Paris, and Université de Paris, Centre de Recherche Épidémiologie et Biostatistiques de Sorbonne Paris Cité, France.

Andrea Doria (A)

Dipartimento di Medicina-DIMED, Azienda Ospedaliera/Università di Padova, Italy.

João Eurico Fonseca (JE)

Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET), Lisbon, and Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal.

Franco Franceschini (F)

Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, and Department of Clinical and Experimental Sciences, University of Brescia, Italy.

Micaela Fredi (M)

Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, and Department of Clinical and Experimental Sciences, University of Brescia, Italy.

Luca Iaccarino (L)

Dipartimento di Medicina-DIMED, Azienda Ospedaliera/Università di Padova, Italy.

Maarten Limper (M)

Department of Rheumatology and Clinical Immunology, Division of Internal Medicine and Dermatology, University Medical Centre Utrecht, Utrecht University, The Netherlands.

Judit Majnik (J)

Semmelweis University, Department of Rheumatology and Clinical Immunology, Hospital of Hospitaller Brothers of St. John of God, Rheumatology and Clinical Immunology, Department of Genetics, Cell- and Immunobiology Semmelweis University, Budapest, Hungary.

Gyorgy Nagy (G)

Semmelweis University, Department of Rheumatology and Clinical Immunology, Hospital of Hospitaller Brothers of St. John of God, Rheumatology and Clinical Immunology, Department of Genetics, Cell- and Immunobiology Semmelweis University, Budapest, Hungary.

Cristina Pamfil (C)

Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, County Emergency Clinical Hospital Cluj, Cluj-Napoca, Romania.

Simona Rednic (S)

Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, County Emergency Clinical Hospital Cluj, Cluj-Napoca, Romania.

John A Reynolds (JA)

Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, and Rheumatology Department, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, UK.

Maria G Tektonidou (MG)

Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Rheumatology Academic Program, School of Medicine, National and Kapodistrian University of Athens, Greece.

Anne Troldborg (A)

Department of Rheumatology, Aarhus University Hospital, and Department of Biomedicine, Aarhus University, Denmark.

Giovanni Zanframundo (G)

Rheumatology Division, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

Marta Mosca (M)

Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, and Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH